TY - JOUR
T1 - Relevance of leukemic stem cells in acute myeloid leukemia
T2 - Heterogeneity and influence on disease monitoring, prognosis and treatment design
AU - Wouters, Rolf
AU - Cucchi, David
AU - Kaspers, Gertjan J.L.
AU - Schuurhuis, Gerrit Jan
AU - Cloos, Jacqueline
N1 - Publisher Copyright:
© Informa UK, Ltd.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Acute myeloid leukemia is a bone marrow disease characterized by a block in differentiation of the myeloid lineage with a concomitant uncontrolled high proliferation rate. Development of acute myeloid leukemia from stem cells with specific founder mutations, leads to an oligoclonal disease that progresses into a very heterogeneous leukemia at diagnosis. Measurement of leukemic stem cell load and characterization of these cells are essential for prediction of relapse and target identification, respectively. Prediction of relapse by monitoring the disease during minimal residual disease detection is challenged by clonal shifts during therapy. To overcome this, characterization of the potential relapse-initiating cells is required using both flow cytometry and molecular analysis since leukemic stem cells can be targeted both on extracellular features and on stem-cell specific signal transduction pathways.
AB - Acute myeloid leukemia is a bone marrow disease characterized by a block in differentiation of the myeloid lineage with a concomitant uncontrolled high proliferation rate. Development of acute myeloid leukemia from stem cells with specific founder mutations, leads to an oligoclonal disease that progresses into a very heterogeneous leukemia at diagnosis. Measurement of leukemic stem cell load and characterization of these cells are essential for prediction of relapse and target identification, respectively. Prediction of relapse by monitoring the disease during minimal residual disease detection is challenged by clonal shifts during therapy. To overcome this, characterization of the potential relapse-initiating cells is required using both flow cytometry and molecular analysis since leukemic stem cells can be targeted both on extracellular features and on stem-cell specific signal transduction pathways.
KW - Acute myeloid leukemia
KW - Clonal shifts
KW - Leukemic stem cells
KW - Minimal residual disease
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84911456464&partnerID=8YFLogxK
U2 - 10.1586/17474086.2014.959921
DO - 10.1586/17474086.2014.959921
M3 - Review article
C2 - 25242511
AN - SCOPUS:84911456464
SN - 1747-4086
VL - 7
SP - 791
EP - 805
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 6
ER -